Clinical Trials Logo

CLL clinical trials

View clinical trials related to CLL.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05209308 Withdrawn - CLL Clinical Trials

Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL

CORAL
Start date: November 22, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.

NCT ID: NCT04694560 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

Start date: December 22, 2020
Phase:
Study type: Observational

The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.

NCT ID: NCT03639324 Withdrawn - Clinical trials for Chronic Lymphocytic Leukemia

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL

RIVe-CLL/SLL
Start date: October 2, 2020
Phase: Phase 1
Study type: Interventional

To determine the recommended phase 2 dose (RP2D) of idelalisib and venetoclax in combination with rituximab in patients with relapsed or refractory Chronic lymphocytic leukemia/ Small lymphocytic lymphoma (CLL/SLL) following a lead-in period with idelalisib and rituximab